Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05216432
Title	First-in-Human Study of Mutant-selective PI3Kalpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Relay Therapeutics, Inc.
Indications	head and neck squamous cell carcinoma Her2-receptor negative breast cancer ovarian clear cell carcinoma cervical cancer Advanced Solid Tumor
Therapies	RLY-2608 Fulvestrant + RLY-2608
Age Groups:	senior \| adult
Covered Countries	USA \| ITA \| FRA \| ESP \| AUS